On Thursday, Exponent received an upgrade to its Relative Strength (RS) Rating, from 62 to 72.
IBD's unique rating measures price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an 80 or better RS Rating in the early stages of their moves. See if Exponent can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
Exponent is not currently showing a potential entry point. See if the stock goes on to build a sound pattern that could kick off a new climb.
Earnings growth declined last quarter from 10% to 2%. But revenue moved higher, from 0% to 2%.
Exponent holds the No. 13 rank among its peers in the Commercial Services-Consulting industry group. CRA International, Leidos Holdings and Huron Consulting Group are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
